ATS 2019 Virtual Final Program

10:24 COPD M.K. Han, MD, MS, Ann Arbor, MI Video Presentation: Pulmonary Vascular Disease Featuring Bradley Maron, MD 10:47 Acute Lung Injury/ARDS C.S. Calfee, MD, San Francisco, CA Video Presentation: Models of Lung Injury Featuring Hasina Outtz Reed, MD, PhD 11:10 Closing Remarks: Looking Ahead G. Gibbons, MD, Bethesda, MD BASIC • CLINICAL • TRANSLATIONAL MINI SYMPOSIUM B14 LATE BREAKING CLINICAL TRIALS 9:15 a.m. - 11:15 a.m. KBHCCD Room D167/D174 (Level 1) Chairing: P. Akuthota, MD, La Jolla, CA T.R. Aksamit, MD, Rochester, MN M.C. McCormack, MHS, MD, Baltimore, MD Oral Presentations 9:15 Eosinophil-Guided Corticosteroid-Sparing Therapy in Hospitalized Patients with Exacerbated COPD(CORTICOsteroid Reduction in COPD (CORTICO-COP)): A Randomized Prospective Multicenter Investigator-Initiated Trial/ P. Sivapalan, T. S. Lapperre, J. Janner, R. R. Laub, M. Moberg, C. S. Bech, F. S. Holm, J. Eklöf, K. Armbruster, P. Sivapalan, C. Mosbech, A. K. Ali, E. Brondum, T. Peick, C. E. Hedsund, N. Seersholm, T. Wilcke, F. Ronholt, H. F. Andreassen, C. S. Ulrik, J. Vestbo, J. S. Jensen, Hellerup, Denmark, p.A7352 9:30 Primary Analysis of a Phase 1/2 Study to Assess MultiStem ® Cell Therapy, a Regenerative Advanced Therapy Medicinal Product (ATMP), in Acute Respiratory Distress Syndrome (MUST-ARDS)/ G. Bellingan, F. Jacono, J. Bannard-Smith, D. Brealey, N. Meyer, D. Thickett, D. Young, A. Bentley, B. McVerry, R. G. Wunderink, K. C. Doerschug, C. Summers, M. Rojas, E. D. Jenkins, A. Ting, London, United Kingdom, p.A7353 9:45 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) at a Dose of 30 mcg/kg-IBW/hr (iNO 30) in Subjects at Risk of Pulmonary Hypertension Associated with Pulmonary Fibrosis (PH-PF) on Long Term Oxygen Therapy/ S. D. Nathan, K. R. Flaherty, M. K. Glassberg Csete, G. Raghu, J. Swigris, R. A. Alvarez, N. A. Ettinger, J. E. Loyd, P. P. Fernandes, H. Gillies, P. Shah, L. H. Lancaster, Falls Church, VA, p.A7354 10:00 Targeted Bronchial Thermoplasty Guided by 129Xe MRI/ C. Hall, J. D. Quirk, C. W. Goss, D. Lew, J. Kozlowski, R. P. Thomen, J. C. Woods, N. Tustison, J. Mugler, L. Gallagher, T. Koch, K. Schechtman, I. Ruset, F. Hersman, M. Castro, Kansas City, KS, p.A7355 10:15 Dupilumab Improves Upper and Lower Airway Outcome Measures in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma: Pooled Results from the SINUS-24 and SINUS-52 Phase 3 Studies/ T. Laidlaw, S. Cho, J. F. Maspero, G. W. Canonica, L. Sher, C. Bachert, J. K. Han, X. Mao, M. Zhang, N. Patel, N. M. H. Graham, H. Staudinger, L. P. Mannent, N. Amin, Boston, MA, p.A7356 10:30 A Randomized Controlled Trial of a Novel Smoking Cessation Smartphone Application Integrated with a Mobile Carbon Monoxide Checker for Smoking Cessation Treatment/ H. Tateno, K. Masaki, A. Nomura, E. Hida, K. Fukunaga, Tokyo, Japan, p.A7357 10:45 Suvratoxumab Reduces Staphylococcus Aureus Pneumonia in High-Risk ICU Patients: Results of the SAATELLITE Study/ B. François, M. Garcia Sanchez, P. Eggimann, P. Dequin, P. Laterre, V. Huberlant, D. Escudero, T. Boulain, C. Bretonniere, J. Pugin, J. Trenado Alvarez, O. Ali, K. Shoemaker, A. Ruzin, D. Vandamme, S. Colbert, T. Bellamy, F. Dubovsky, H. Jafri, SAATELLITE Study Group, Limoges, France, p.A7358 11:00 Sustainability and Durability of Culture Conversion in Patients Receiving Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Mycobacterium Avium Complex Lung Disease (MAC-LD) in the CONVERT Study/ D. E. Griffith, R. Thomson, D. J. Addrizzo-Harris, S. K. Field, J. van Ingen, R. J. Wallace, Jr, C. Coulter, K. Mange, J. Nezamis, K. L. Winthrop, Tyler, TX, p.A7359 BASIC • CLINICAL • TRANSLATIONAL MINI SYMPOSIUM B15 IMMUNOTHERAPY FOR LUNG DISEASE 9:15 a.m. - 11:15 a.m. KBHCCD Room C146 (Level 1) Chairing: G.M. Gauvreau, PhD, ATSF, Hamilton, Canada J.L. Cho, MD, Iowa City, IA Oral Presentations 9:15 Tezepelumab Treatment Effect on Annualized Rate of Exacerbations by Baseline Biomarkers in Uncontrolled Severe Asthma Patients: Phase 2b PATHWAY Study/ J. Corren, E. Garcia Gil, J.R. Parnes, T.-H. Pham, J.M. Griffiths, Los Angeles, CA, p.A2621 9:30 The Impact of Tezepelumab on Hospitalization and Emergency Department Visits in Patients with Severe Uncontrolled Asthma: Results from the Pathway Phase 2b Trial/ J. Corren, S. Chen, L. Callan, E. Garcia Gil, Los Angeles, CA, p.A2622 9:45 Oral TORC1 Inhibitor Dactolisib Enhances Immune Function and Reduces the Incidence of Respiratory Tract Infections in Elderly Subjects with Asthma/ J. Mannick, S. Shergill, G. Teo, Boston, MA, p.A2623 ATS 2019 • Dallas, TX 130 MONDAY • MAY 20